Our technology will bring new medicines for diseases of unmet clinical need
Intellectual Property
GyreOx has protected its proprietary technology with four families of patent applications, with some now granted, covering both rationally engineered enzymes and the gyrocycle production process.
“In vitro production of cyclic peptides” (WO2014/001822, priority date June 2012) granted in Australia, USA and Europe
"Modified heterocyclase” (WO2016/071422, priority date November 2014), accepted for grant in the USA and in the national phase in Europe
"Macrocyclisation tags” (WO2019/048634, priority date September 2017)
A further application to protect the technology enabling the transfer of resin-bound intermediates from organic to aqueous phase was filed in April 2019